The most successful clinical application is the methylation status of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter, which predicts radiation response and prognosis in glioblastoma [92] Epigenetic control also plays an important role in radiation response in NSCLC. The gene discussed is MGMT; the disease is glioblastoma.